Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 3:04 AM ET

Life Sciences Tools and Services

Company Overview of VIB BV

Company Overview

VIB BV is a life sciences research institute that performs basic research into the molecular foundations of life. It focuses on translating scientific results into pharmaceutical, agricultural, and industrial applications. The company performs research in the areas of bioinformatics, cancer, cardiovascular medicine, developmental biology, inflammation and immunity, microbiology, neuroscience, plant biology, proteomics, structural biology, and systems biology. Its research services include sequencing and genotyping; sequencing, microarrays, and transcriptomics; assay development and compound screening; protein production, purification, and analysis; proteomics analysis; nanobody production an...

Rijvisschestraat 120

Gent,  9052

Belgium

Founded in 1995

Phone:

32 9 244 66 11

Fax:

32 9 244 66 10

Key Executives for VIB BV

Managing Director
Managing Director
Chief Financial Officer
Secretary and Director
Human Resources Director
Compensation as of Fiscal Year 2015.

VIB BV Key Developments

ThromboGenics and VIB Launch New Oncology Company, Oncurious NV

ThromboGenics NV announced the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. TB-403 is a humanized monoclonal antibody against placental growth factor. PlGF is expressed in several types of cancer, including medulloblastoma. High expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall survival. Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Treatment with TB-403 in relevant animal models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival. The antibody can potentially be used in other pediatric cancer indications, including neuroblastoma. Oncurious now plans to start a Phase I/IIa program with TB-403 in medulloblastoma patients. Enrollment of the first patient is expected for the end of 2015. The favorable safety profile of TB-403 has already been demonstrated in clinical trials in patients with other diseases. BioInvent International AB will act as a co-development partner for this oncology project. ThromboGenics has retained the exclusive license for use of TB-403 in ophthalmic indications.

Similar Private Companies By Industry

Company Name Region
Unibioscreen S.A. Europe
Bio-Rad Laboratories NV Europe
BV Transgenic Services SA Europe
reMYND nv Europe
Federa SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIB BV, please visit www.vib.be. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.